The untapped potential of genetically engineered mouse models in chemoprevention research: Opportunities and challenges

Cancer Prevention Research

Volumn 1, Issue 3, 2008, Pages 161-166

  Abate Shen, Cory ^a   Brown, Powel H ^c   Colburn, Nancy H ^d   Gerner, Eugene W ^e   Green, Jeffery E ^f   Lipkin, Martin ^b   Nelson, William G ^g   Threadgill, David ^h  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BIOLOGICAL MODEL; CHEMOPROPHYLAXIS; DISEASE MODEL; DRUG SCREENING; EVALUATION; GENETICS; HUMAN; METHODOLOGY; MOUSE; NEOPLASM; PRODUCTIVITY; REVIEW; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; CHEMOPREVENTION; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; EFFICIENCY; GENES, TUMOR SUPPRESSOR; HUMANS; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 57349139331     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0076     Document Type: Review

References (46)

1. Green JE, Hudson T. The promise of genetically engineered mice for cancer prevention studies. Nat Rev Cancer 2005;5:184-98.
2. Van Dyke T, Jacks T. Cancer modeling in the modern era: progress and challenges. Cell 2002; 108:135-44.
3. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007;9:212.
4. Nelson WG, DeWeese TL, DeMarzo AM. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 2002; 21:3-16.
5. Garrett WS, Lord GM, Punit S, et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 2007;131:33-45.
6. Rangarajan A, Weinberg RA. Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer 2003;3: 952-9.
7. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer 2007;7:645-58.
8. Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 2006;12:5277-87.
9. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006;5: 741-54.
10. Lee HW, Blasco MA, Gottlieb GJ, Horner JW II, Greider CW, DePinho RA. Essential role of mouse telomerase in highly proliferative organs. Nature 1998;392:569-74.
11. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436:725-30.
12. Maser RS, Choudhury B, Campbell PJ, et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007;447:966-71.
13. Moody SE, Perez D, Pan TC, et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 2005;8:197-209.
14. Ouyang X, Jessen WJ, Al-Ahmadie H, et al. Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res 2008;68:2132-44.
15. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4:437-50.
16. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 2004;6:185-95.
17. Moody SE, Sarkisian CJ, Hahn KT, et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2002;2:451-61.
18. Hanahan D, Wagner EF, Palmiter RD. The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev 2007;21:2258-70.
19. Lang GA, Iwakuma T, Suh YA, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004;119:861-72.
20. Olive KP, Tuveson DA, Ruhe ZC, et al. Mutant p53 gain of function in two mouse models of Li- Fraumeni syndrome. Cell 2004;119:847-60.
21. Zhang J, Schweers B, Dyer MA. The first knockout mouse model of retinoblastoma. Cell Cycle 2004;3:952-9.
22. Branda CS, Dymecki SM. Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. Dev Cell 2004;6:7-28.
23. Sweet-Cordero A, Mukherjee S, Subramanian A, et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 2005;37:48-55.
24. Fujimoto N, Wislez M, Zhang J, et al. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 2005;65:11478-85.
25. Shaw AT, Kirsch DG, Jacks T. Future of early detection of lung cancer: the role of mouse models. Clin Cancer Res 2005;11:4999-5003S.
26. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999;4:199-207.
27. Chin L, Tam A, Pomerantz J, et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999;400:468-72.
28. Fisher GH, Orsulic S, Holland E, et al. Development of a flexible and specific gene delivery system for production of murine tumor models. Oncogene 1999;18:5253-60.
29. Fomchenko EI, Holland EC. Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 2006;12:5288-97.
30. Silva J, Chang K, Hannon GJ, Rivas FV. RNAinterference- based functional genomics in mammalian cells: reverse genetics coming of age. Oncogene 2004;23:8401-9.
31. Dickins RA, McJunkin K, Hernando E, et al. Tissue- specific and reversible RNA interference in transgenic mice. Nat Genet 2007;39:914-21.
32. Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer 2002; 2:11-8.
33. Muzumdar MD, Luo L, Zong H. Modeling sporadic loss of heterozygosity in mice by using mosaic analysis with double markers (MADM). Proc Natl Acad Sci U S A 2007;104:4495-500.
34. Lamprecht SA, Lipkin M. Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nat Rev Cancer 2003;3: 601-14.
35. Lipkin M, Lamprecht S. Modeling human colorectal cancer in mice for chemoprevention studies. In: Kelloff GJHE, Sigman CC, editors. Cancer Chemoprevention Volume 2: Strategies for Cancer Chemoprevention. Totowa NJ: Humana Pres Inc.; 2005. p. 543.
36. Kucherlapati R, Lin DP, Edelmann W. Mouse models for human familial adenomatous polyposis. Semin Cancer Biol 2001;11:219-25.
37. Lanza E, Yu B, Murphy G, et al. The polyp prevention trial continued follow-up study: no effect of a low-fat, high-fiber, high-fruit, and -vegetable diet on adenoma recurrence eight years after randomization. Cancer Epidemiol Biomarkers Prev 2007;16: 1745-52.
38. Lanza E, Hartman TJ, Albert PS, et al. High dry bean intake and reduced risk of advanced colorectal adenoma recurrence among participants in the polyp prevention trial. JNutr 2006; 136:1896-903.
39. Faca VM, Song KS, Wang H, et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 2008;5:e123.
40. Whiteaker JR, Zhang H, Zhao L, et al. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. JProteome Res 2007;6:3962-75.
41. Hunter KW. Host genetics and tumour metastasis. Br JCancer 2004;90:752-5.
42. Roberts RB, Arteaga CL, Threadgill DW. Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. Cancer Cell 2004;5:115-20.
43. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 2007;21:379-84.
44. Pearson KJ, Lewis KN, Price NL, et al. Nrf2 mediates cancer protection but not prolongevity induced by caloric restriction. Proc Natl Acad Sci U S A 2008;105:2325-30.
45. Dove WF, Clipson L, Gould KA, et al. Intestinal neoplasia in the ApcMin mouse: independence from the microbial and natural killer (beige locus) status. Cancer Res 1997;57:812-4.
46. Shen Q, Uray I, Li Y, et al. Targeting the AP-1 Transcription factor for the prevention of estrogen- negative mammary tumors. Cancer Prev Res 2008;1:45-55.